
Alibaba Reality Check: The Widowmaker
BABA trades at 19.6x forward P/E with $80B in net cash—but a deflationary price war and geopolitical risk make this a widowmaker trade. Is the AI pivot real?
Nurse Mercy dissects earnings reports, SEC filings, and market trends. No bedside manner—just the diagnosis Wall Street won't give you.

BABA trades at 19.6x forward P/E with $80B in net cash—but a deflationary price war and geopolitical risk make this a widowmaker trade. Is the AI pivot real?

CVNA trades at 78-100x P/E with $192M in insider selling and forensic accounting allegations. Q4 earnings on Feb 18 is a binary event—squeeze or collapse.

Uber reported $6.9B net income—but only $770M was real. With Tesla's Cybercab targeting $0.50/mile and the CEO dumping shares, the 'cheap' P/E is a mirage.

RKLB trades at 78x sales while insiders dump $419M. With the Neutron tank rupture pushing timelines, is this SpaceX killer priced for perfection or failure?

Bitcoin down 39% from ATH as leverage unwinds. Nurse Mercy dissects the macro infection, quantum fears, and miner capitulation driving the crash.

AMD trades at 117x earnings while Nvidia sits at 46x. With 160M warrants diluting shareholders for OpenAI, is this a growth story or a growth trap?

Gold, Silver, and Copper aren't siblings anymore—correlation is dead. Silver's Shanghai premium and Copper's contango mean your basket ETF is bleeding.

PLTR trades at 159x earnings while insiders dumped $167M. With an Army security scandal brewing, is this AI darling priced for god?

SanDisk soared 2,300% in a year—but $5 billion in forced selling hits in 25 days. Is SNDK AI gold or a squeeze trap about to collapse?

Humana dropped 21% after earnings. Revenue grew 11%, but the core business is bleeding out. Is this 'cheap' stock a value trap?
Don't just read about market mistakes—find out if you're making them.
Analyze My Portfolio